Carotid Baroreceptor Stimulation Improves Pulmonary Arterial Remodeling and Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS JACC: Basic to Translational Science Pub Date : 2024-04-01 DOI:10.1016/j.jacbts.2024.01.012

Jing Wang MM , Jie Chen MM , Ling Shu MM , Ruoliu Zhang MB , Mingyan Dai MD , Xuesheng Fang MB , Zhiling Hu MB , Lingling Xiao MB , Zhaoqing Xi MB , Junxia Zhang MD , Mingwei Bao MD

{"title":"Carotid Baroreceptor Stimulation Improves Pulmonary Arterial Remodeling and Right Ventricular Dysfunction in Pulmonary Arterial Hypertension","authors":"Jing Wang MM , Jie Chen MM , Ling Shu MM , Ruoliu Zhang MB , Mingyan Dai MD , Xuesheng Fang MB , Zhiling Hu MB , Lingling Xiao MB , Zhaoqing Xi MB , Junxia Zhang MD , Mingwei Bao MD","doi":"10.1016/j.jacbts.2024.01.012","DOIUrl":null,"url":null,"abstract":"<div><p>Autonomic nervous system imbalance is intricately associated with the severity and prognosis of pulmonary arterial hypertension (PAH). Carotid baroreceptor stimulation (CBS) is a nonpharmaceutical intervention for autonomic neuromodulation. The effects of CBS on monocrotaline-induced PAH were investigated in this study, and its underlying mechanisms were elucidated. The results indicated that CBS improved pulmonary hemodynamic status and alleviated right ventricular dysfunction, improving pulmonary arterial remodeling and right ventricular remodeling, thus enhancing the survival rate of monocrotaline-induced PAH rats. The beneficial effects of CBS treatment on PAH might be mediated through the inhibition of sympathetic overactivation and inflammatory immune signaling pathways.</p></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":null,"pages":null},"PeriodicalIF":8.4000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X2400041X/pdfft?md5=998f48ef8365f3b6ee9c3a2cdfdc1acb&pid=1-s2.0-S2452302X2400041X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X2400041X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Autonomic nervous system imbalance is intricately associated with the severity and prognosis of pulmonary arterial hypertension (PAH). Carotid baroreceptor stimulation (CBS) is a nonpharmaceutical intervention for autonomic neuromodulation. The effects of CBS on monocrotaline-induced PAH were investigated in this study, and its underlying mechanisms were elucidated. The results indicated that CBS improved pulmonary hemodynamic status and alleviated right ventricular dysfunction, improving pulmonary arterial remodeling and right ventricular remodeling, thus enhancing the survival rate of monocrotaline-induced PAH rats. The beneficial effects of CBS treatment on PAH might be mediated through the inhibition of sympathetic overactivation and inflammatory immune signaling pathways.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

刺激颈动脉感受器可改善肺动脉高压的肺动脉重塑和右心室功能障碍

自主神经系统失衡与肺动脉高压（PAH）的严重程度和预后密切相关。颈动脉气压感受器刺激（CBS）是一种非药物的自律神经调节干预方法。本研究探讨了 CBS 对单克罗林诱导的 PAH 的影响，并阐明了其潜在机制。结果表明，CBS能改善肺血流动力学状态，缓解右心室功能障碍，改善肺动脉重塑和右心室重塑，从而提高单克隆肾上腺素诱导的PAH大鼠的存活率。CBS治疗对PAH的有益作用可能是通过抑制交感神经过度激活和炎症免疫信号通路介导的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.